Monograph
C07AB03 - Atenolol |
Not porphyrinogenic |
NP |
Rationale
Considerable clinical experience points to non-porphyrinogenicity.
Chemical description
Hydrophilic catecholamine derivative
Therapeutic characteristics
Selective antagonist of adrenergic beta1 adrenoceptors (beta blocker) for the treatment of e.g. hypertension, angina, dysrhythmias, myocardial infarction. Adverse reactions that can mimick porphyria symptoms are fatigue/muscle weakness, depression, sleep disturbance, gastrointestinal effects (nausea and vomiting, diarrhoea, constipation and abdominal cramping).
Hepatic exposure
Significant
Metabolism and pharmacokinetics
Less than 10% of an oral dose is metabolized, the rest being excreted in unchanged form in urine. 85 to 100 % of an intravenous dose is excreted unchanged in the urine.
Preclinical data
None
Personal communication
Used in Swedish porphyria ward:
IPNet drug reports
Uneventful use reported in 75 patients with acute porphyria.
References
| # |
Citation details |
PMID |
|---|
| * | Scientific articles |
| 1. |
Pathologic quiz case. A 35 year old woman with a history of arrhythmia and liver failure. Arch Pathol Lab Med 2002;126(6):751-2.
Mikolaenko MD, Conner MG. |
|
| 2. |
Use of sufentanil and atracurium anesthesia in a patient with acute porphyria undergoing coronary artery bypass surgery. J Cardiothorac Vasc Anesth 1995;9(1):75-8.
Sneyd JR, Kreimer-Birnbaum M et al. |
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Serbia
